Therefore, our data suggests that measurements of monocyte CD163, rather than sCD163, serve as a better surrogate marker for pathophysiological impact in insulin resistance for patients with type 2 diabetes. This evidence concerns the gene CD163 and type 2 diabetes mellitus.